ALNA.OQ
Latest Trade
2.17USDChange
0.00(0.00%)Volume
25,281Today's Range
-
--52 Week Range
-
3.39As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 2.17 |
|---|---|
Open | 0.00 |
Volume | 25,281 |
3M AVG Volume | 21.93 |
Today's High | -- |
Today's Low | -- |
52 Week High | 3.39 |
52 Week Low | 0.53 |
Shares Out (MIL) | 48.52 |
Market Cap (MIL) | 81.51 |
Forward P/E | -1.75 |
Dividend (Yield %) | -- |
Orin Hirschman Reports 8.0% Passive Stake In Allena Pharmaceuticals Inc As Of January 20, 2021 - SEC Filing
Allena Pharmaceuticals Announces $10 Million Bought Deal Offering
Allena Pharma Announces Initial Data From Phase 1 Trial Of ALLN-346
Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. It is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its pipeline includes reloxaliase and ALLN-346. Reloxaliase is an oral enzyme therapeutic that is being developed for the treatment of hyperoxaluria. ALLN-346 is designed to be an orally-administered non-absorbed urate-degrading enzyme. ALLN-346 is being developed to degrade urate in the gastrointestinal (GI) tract.
Industry
Biotechnology & Drugs
Contact Info
1 Newton Executive Park Ste 202
NEWTON, MA
02462-1435
United States
+1.617.4674577
http://www.allenapharma.com/Executive Leadership
Alexey L. Margolin
Chairman of the Board, Co-Founder
Louis Brenner
President, Chief Executive Officer, Director
Edward Wholihan
Chief Financial Officer
Geoffrey Swire
Acting Chief Operating Officer, Interim Principal Operating Officer, Senior Vice President - Corporate Development
Ann Calby Miller
Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 3.52 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 54.30 |
LT Debt To Equity (MRQ) | 54.30 |
Return on Investment (TTM) | -112.54 |
Return on Equity (TTM) | -90.84 |
* EMPERY ASSET MANAGEMENT LP REPORTS 8.71% PASSIVE STAKE IN ALLENA PHARMACEUTICALS AS OF JUNE 3 - SEC FILING Source text - https://bit.ly/2ARAr0b Further company coverage:
* ALLENA PHARMACEUTICALS ANNOUNCES $15.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER 2019 AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS ANNOUNCES STREAMLINED DESIGN FOR URIROX-2, SECOND PIVOTAL CLINICAL TRIAL OF RELOXALIASE FOR ENTERIC HYPEROXALURIA
* ALLENA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.